Investors can bid for a minimum of 15 equity shares, with bids thereafter available in multiples of 15 shares. At the upper end of the price band, the minimum investment will be Rs 14,820.
The IPO is proposed to be listed on both the BSE and NSE, with the tentative listing date scheduled for September 1, 2026. The allotment is likely to be finalised on August 28, 2026.
The company is offering eligible employees a Rs 90-per-share discount on bids made through the employee reservation portion.
Valuation Under the Spotlight
Symbiotec Pharmalab’s IPO valuation is likely to attract close attention from investors. Based on diluted earnings per share for fiscal 2026, the price-to-earnings (P/E) ratio stands at 49.37 times at the lower end of the price band and rises to 52.00 times at the upper end.## Where Will the IPO Proceeds Go?
The primary objective of the issue is to strengthen the company’s balance sheet. Symbiotec Pharmalab plans to use the proceeds for prepayment and/or repayment, either fully or partially, of certain outstanding borrowings. The remaining funds will be utilised for general corporate purposes.## Symbiotec Pharmalab
Founded in 2002, Symbiotec Pharmalab operates across the biopharmaceutical and biotechnology space, developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients and specialised products for domestic and international markets.The company’s journey began with laboratory-scale manufacturing of steroidal-hormone APIs in 1995. Over the years, it has expanded into an industrial-scale, backward-integrated manufacturing platform serving the pharmaceutical, nutraceutical and wellness sectors.
Research-driven manufacturing, quality and sustainability form key elements of its business strategy. Its manufacturing operations have also secured approvals and certifications from several international regulatory bodies, including the US FDA, EU-GMP authorities and South Korea’s Ministry of Food and Drug Safety.
As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing plants. Together, these facilities had a maximum capacity of 584.67 metric tonnes (MT) for chemical synthesis and 300 kilolitres of fermentation capacity.
The combination of backward integration, specialised API capabilities and international regulatory approvals gives the company an established position in a segment where manufacturing quality and regulatory compliance can be critical differentiators.
IPO Management Team
The IPO is being managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial. MUFG Intime India Pvt. Ltd. is acting as the registrar to the issue.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)
Subscribe to ET Prime and read the Economic Times ePaper Online.and Sensex Today.
Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price